WATCH LIVE: Investing.com reveals the top 10 stock picks for 2026
DUBLIN - Investment management giant BlackRock, Inc. has disclosed a 7.05% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Monday.
The disclosure, made under Irish Takeover Panel rules, shows BlackRock holds 6,891,957 ordinary shares in the pharmaceutical company as of November 28, 2025. The filing indicates BlackRock has no significant short positions, with only 4,268 shares in cash-settled derivatives representing less than 0.01% of the company.
The regulatory document also details recent transactions, including the purchase of 848 shares at $21.49 per share, along with stock lending activities involving 168,600 shares being loaned out and 439,800 shares returned from loans.
The disclosure was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
BlackRock’s filing does not indicate any indemnity arrangements or agreements related to options or derivatives regarding Avadel securities.
The disclosure comes in the form of an opening position disclosure, which is typically required when a company becomes subject to takeover rules. However, the filing does not specify whether Avadel is currently involved in any takeover discussions or proceedings.
Avadel Pharmaceuticals is a specialty pharmaceutical company that trades on the Nasdaq exchange.
The information was disclosed through a regulatory filing submitted to the London Stock Exchange’s Regulatory News Service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.